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Abstract: We identify families in which early onset multiple primary melanoma co-segregates 
with inactivating mutations in the protection of telomeres 1 (POT1) gene. We show that 
missense mutations of POT1 in three families alter key residues of the oligonucleotide-
/oligosaccharide-binding (OB) domains, disrupting telomere binding, leading to increased 
telomere length. Our results suggest POT1 mutations strongly predispose to melanoma 
formation.  
 
Main text: Mutations in CDKN2A account for 40-50% of familial melanoma cases1, with rare 
mutations in CDK4, BRCA2, BAP1, and the promoter of TERT, also linked to the disease2-5. Here 
we set out to identify high-penetrance genes accounting for the ~50% of cases of familial 
melanoma that cannot be attributed to mutations in known genes.  
 
To achieve this, we sequenced 184 melanoma cases from 105 pedigrees (168 exomes and 16 
whole genomes) recruited in the United Kingdom, the Netherlands, and Australia that had been 
screened and found negative for pathogenetic variants in CDKN2A and CDK4. The patients 
sequenced came from pedigrees with between two and eleven cases of melanoma (169 cases), or 
were single cases that presented with either multiple primary melanomas (MPM), multiple 
primary cancers, one of which was melanoma, and/or an early age of onset (<4th decade) (15 
cases) (Supplementary Methods, Supplementary Tables 1-2). Two-case families were 
preferentially selected for those enriched with cases of MPM. Exome capture and sequencing 
resulted in on average 84% of target bases being covered ≥ 10x across the autosomes and sex 
chromosomes. Whole genomes were sequenced to at least 27x mapped coverage. Focusing on 
coding regions we called nucleotide variants and filtered these data removing positions found in 
Phase 1 of the 1000 Genomes Project6, dbSNP build 135 (see URLs), and variants called from 
805 in-house control exomes. No known pathogenetic variants in BAP1 or BRCA2 were found, 
while capillary sequencing of the TERT promoter identified a six-case pedigree carrying the -
57bp mutation2 that was excluded from further analysis. Co-segregating variants found in all 
members of a sequenced pedigree, that were predicted to affect protein structure or function, 
were taken forward for further analysis (Supplementary Methods).  
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The abovementioned analysis left 23,051 novel variants that were either private to a pedigree or 
individual. We therefore focused on genes with co-segregating variants from the 26 pedigrees for 
which we had sequence data for three or more members (314 genes) (Supplementary Table 3). 
Of particular interest were 6 genes (defined by GO/PubMed analysis) linked to biological 
processes such as G1 cell cycle progression or the regulation of telomere length or integrity, since 
high-penetrance mutations in CDKN2A and CDK4, and genetic variation in the vicinity of TERT, 
ATM and PARP1 has been associated with melanoma susceptibility7-9. Analysis of missense and 
disruptive variants (nonsense, essential splice site and frameshift mutations) led us to identify a 
5-case pedigree (id: UF20) carrying a Tyr89Cys change (GRCh37 chr. 7: g. 124503684T>C) in 
the highly conserved N-terminal oligonucleotide-/oligosaccharide-binding (OB) domain of the 
POT1 (protection of telomeres 1) gene product10, and then a further two families with non-
synonymous OB domain changes (id: UF31, Gln94Glu, g. 124503670G>C and id: UF23, 
Arg273Leu, g. 124493077C>A) (Fig. 1, Table 1, Supplementary Figs. 1&2a-c, 
Supplementary Tables 1, 4-5). Remarkably, Gln94 has been found to be recurrently somatically 
mutated (Gln94Arg) in chronic lymphocytic leukemia (CLL), where ~5% of cases carry POT1 
mutations that cluster in the OB domains11. We also identified a 6-case family (id: AF1), 3 
members of which were sequenced, who carried an invariant essential splice acceptor mutation 
in intron 17-18 (g.124465412C>T). This variant was scored as deleterious by the MaxEntScan 
algorithm12 and was shown to affect transcript splicing by RT-PCR and sequencing (Fig. 1, 
Table 1, Supplementary Methods, Supplementary Figs. 2d-e&3, Supplementary Tables 4-
5). Pedigrees UF20 and AF1 are among our largest families, suggesting a strong association 
between POT1 mutations and melanoma formation. Importantly, the identification of POT1 
mutations in 4/105 melanoma families represents a statistically significant enrichment 
(P=0.0033) of variants compared to a control dataset of 520 exomes in which we found only one 
missense mutation passing our filters, and this was located outside the OB domains of POT1 
(Supplementary Methods, Supplementary Fig. 4, Supplementary Table 6). None of the four 
variants mentioned above (three missense and the splice acceptor mutation) were found by 
genotyping 2,402 additional controls (Supplementary Methods, Supplementary Table 6). We 
also genotyped these positions across 1,739 population-based melanoma cases from a case-
control series. We found one case with MPM and early onset, who carried the Arg273Leu 
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variant, and another case who carried the essential splice site mutation, whose sibling was also a 
melanoma patient who was diagnosed in the 5th decade (Supplementary Methods).   
 
All of the missense variants identified in POT1 disrupt amino acids completely conserved 
throughout Eutherian evolution (Fig. 1b) and code for amino acids that are more evolutionarily 
conserved than the average for other OB domain residues (Supplementary Methods). 
Importantly, all 9 confirmed mutation carriers from the familial cohort developed melanoma, 
with their presentation ranging from 1 primary melanoma (4 cases) to 8 melanomas, from 25 to 
80 years of age. One mutation carrier from these familial cases also developed breast cancer at 
65 and another small cell lung cancer at 50 (pedigree UF20), while 4 of the 12 untested first 
degree relatives of mutation carriers, who were over the age of 30 years or deceased, were 
reported to have developed cancer. These malignancies included melanoma (pedigrees UF20 and 
UF31), endometrial cancer (pedigree UF20) and brain tumors (pedigrees UF20 and UF23). 
Intriguingly, the pedigree with the splice acceptor mutation (AF1) had a patient with a history of 
melanoma and CLL, in keeping with a role for POT1 in CLL development11. Collectively, these 
data suggest a possible role for germline POT1 mutations in susceptibility to a range of cancers 
in addition to melanoma. 
 
To test whether the effect of the identified missense variants might be similar to that of the 
somatic mutations found in CLL in that they disrupt telomere binding, we examined the structure 
of POT1 bound to a telomere-like polynucleotide (dTUdAdGdGdGdTdTdAdG) (PDB 
3KJP)13,14. According to this model, all three mutated residues (Tyr89, Gln94 and Arg273) are 
amongst 24 residues located in close proximity (<3.5Å) to the telomeric polynucleotide11 (Fig. 
2a). Arg273 interacts with the oxygen at position 2 of the telomeric dT7, whereas Gln94 and 
Tyr89 both interact with the G deoxynucleotide at position 4. Therefore, as described for the 
somatic mutations in CLL, the POT1 variants we identified are expected to weaken or abolish 
the interaction between POT1 and telomeres. Analysis of nucleotides coding for these 24 OB 
domain residues identified one non-synonymous change in 6,498 control exomes15 compared to 
3 in 105 families, a highly significant enrichment of mutations in the melanoma cohort 
(P=1.54x10-5) (Supplementary Methods, Supplementary Tables 6-7). 
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To test formally that the OB mutations we identified disrupt POT1 function we assessed the 
ability of in vitro-translated POT1 Tyr89Cys, Gln94Glu and Arg273Leu proteins to bind to 
(TTAGGG)3 sequences, with electromobility shift assays revealing a complete abolition of 
mutant POT1-DNA complex formation (Fig. 2b, Supplementary Methods, Supplementary 
Fig. 5). Importantly, the POT1 Tyr36Asn and Tyr223Cys variants recently described in CLL by 
Ramsay et al11, which appear to be functionally analogous to the variants we describe here, 
promote uncapping of telomeres, telomere length extension and chromosomal aberrations and 
thus promote tumorigenesis11. Using DNA sequence from 41 patients for whom we had 
unmapped read data we estimated telomere length by counting TTAGGG repeats (See Ref. 16). 
All three members of pedigree UF20, carrying the Tyr89Cys mutation, were found to have 
telomeres that were as much as 3.5-fold longer than POT1 wild-type controls (P<0.0002, Fig. 
2c). This result was confirmed by telomere length PCRs, which also showed longer telomeres for 
patients carrying the Gln94Glu and Arg273Leu variants (Fig. 2d, Supplementary Methods). 
Thus, missense mutations in the OB domains of POT1 not only abolish telomere binding, they 
are also associated with increased telomere length, a key factor influencing risk of melanoma17. 
Importantly, OB domain variants that disrupt the interaction of POT1 with telomeric ssDNA are 
thought to function as dominant-negative alleles11,18, yet as we show here are compatible with 
life, suggesting additional somatic events are required to promote tumorigenesis. Analysis of 
somatic variants within POT1 from the COSMIC19 and IntOGen20 databases (TCGA/ICGC data) 
across 14 cancer types show a tendency for variants to result in missense mutations (P<0.03), to 
hit residues in close proximity to DNA (P<0.02), and to have a high functional bias (P<0.03) 
(Supplementary Methods). This result suggests that although rare, somatic POT1 mutations 
may drive tumorigenesis across multiple histologies. 
 
Here we describe germline mutations in the gene encoding the telomere-associated protein POT1 
in almost 4% of CDKN2A/CDK4-negative familial melanoma pedigrees and in 2/34 (5.8%) 5+ 
case pedigrees, making POT1 the second most frequently mutated high-penetrance familial 
melanoma gene reported to date. In combination with the recently described TERT promoter 
mutation2, these findings significantly extend our understanding of a novel mechanism 
predisposing to the development of familial melanoma. Since the dysregulation of telomere 
protection by POT1 has recently been identified as a target for potential therapeutic 
 7
intervention21, in the future, it may be possible that early identification of families with POT1 
mutations may facilitate better management of their disease.  
 
 
Methods 
Methods and associated references are available in the online version of the paper.  
 
Figure legends 
 
Fig. 1. Mutations in POT1 predispose to familial melanoma. a) We identified four pedigrees 
carrying deleterious mutations in the protection of telomeres 1 (POT1) gene. Shown are a 5- 
(UF20) and a 6-(AF1) member pedigree carrying the disruptive Tyr89Cys OB domain mutation 
and an essential splice acceptor mutation, respectively. Please note that pedigrees have been 
adjusted to protect the identity of the families without a loss of scientific integrity. CMM; 
cutaneous malignant melanoma. CLL; chronic lymphocytic leukemia. The patients that were 
sequenced have a red outline. All melanomas were confirmed by histological analysis with the 
exception of two cases (*). The number of primary melanomas in each patient is indicated. b) 
Highly conserved residues of POT1 are mutated in familial melanoma. Shown are the positions 
of the mutations identified on the POT1 protein (top panel), and on an amino acid alignment 
(missense mutations, bottom panel).  
 
Fig. 2. Missense mutations in POT1 disrupt the interaction between POT1 and single-
stranded DNA and lead to elongated telomeres. a) Shown is the location of the POT1 residues 
Tyr89, Gln94 and Arg273 in the N-terminal two oligonucleotide-/oligosaccharide-binding (OB) 
domains, in green. A telomere-like polynucleotide sequence is shown in orange. All three 
substitutions are predicted to disrupt the association of POT1 with telomeres. b) Mutant 
Tyr89Cys, Gln94Glu and Arg273Leu POT1 proteins are unable to bind telomeric (TTAGGG)3 
sequences as revealed by an electromobility shift assay. The Tyr223Cys POT1 mutant was used 
as a positive control representing a known disruptive mutation11. c) Calculation of telomere 
length from exome sequence data. The method used is analogous to the one described in Ref. 16. 
Relative telomere lengths for the three sequenced members of pedigree UF20 are shown 
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alongside the mean telomere length of 38 (all) other melanoma cases who were sequenced 
alongside, but were wildtype for POT1. Error bars indicate one standard deviation. A Wilcoxon 
rank sum test was performed comparing the telomere length of the 3 Tyr89Cys cases to the 38 
non-carrier controls. d) PCR-based estimate of telomere length. Negative mean ΔCt values, 
which correlate positively with telomere length, for POT1 missense mutation carriers and non-
carrier family controls are shown against a distribution of values from 258 POT1 non-mutation 
carrier controls (Supplementary Methods). The black line represents a Gaussian kernel density 
estimate for this set using Silverman’s “rule-of-thumb”22 as the smoothing bandwidth. Orange 
dots represent members of pedigree UF20; pink, UF31; blue, UF23; red, individual CT1663 from 
the Leeds Melanoma Case-control study carrying the Arg273Leu variant (Supplementary Table 
5). The number of biological replicates for each case ranged from 1 to 4, each with two technical 
replicates for the POT1 missense mutation carriers and non-carrier family controls. Between one 
and two technical replicates were performed for the 258 POT1 non-mutation carrier controls. 
Error bars indicate the standard error of the mean. 
 
Table 1. POT1 mutations identified in this study. 
Pedigree Num. cases in pedigree 
Num. of 
carriers / 
num. of 
tested 
cases 
Mutation 
(genomic 
coordinates) 
HGVS 
name* Exon 
Amino acid 
change 
Mutation 
type 
Bioinformatic prediction tools 
SIFT23 PolyPhen 224 CAROL
25 
UF20 5 4/4 g.124503684T>C c.266A>G 8 Tyr89Cys Missense Deleterious Probably damaging Deleterious 
UF31 2 1/1 g.124503670G>C c.280C>G 8 Gln94Glu Missense Tolerated Probably damaging Deleterious 
UF23 2 1/2** g.124493077C>A c.818G>T 10 Arg273Leu† Missense Deleterious 
Probably 
damaging Deleterious 
AF1 6 3/3 g.124465412C>T c.1687-1G>A - -†† 
Splice 
acceptor 
(intronic, 
between ex. 
17-18) 
- - - 
 
*The reference transcript, taken from the Ensembl database (release 70) is POT1-001 (ENST00000357628). 
**A second case within this pedigree had a different clinical presentation (solitary melanoma in situ) in the 6th 
decade and did not carry the Arg273Leu variant.  
†This variant was also detected in a melanoma case from population-based case-control series that presented with 
MPMs and an early age of onset (see Supplementary Methods). 
††This variant was also detected in a case from population-based case-control series that presented with melanoma 
and who had a sibling with a previous diagnosis of the disease (see Supplementary Methods).  
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URLs 
dbSNP135, http://www.ncbi.nlm.nih.gov/projects/SNP/; European Genome-phenome Archive, 
http://www.ebi.ac.uk/ega/. 
 
 
Accession codes 
Sequence data has been deposited at the European Genome-phenome Archive (EGA), hosted at 
the European Bioinformatics Institute, under accession EGAS00001000017.  
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